Nationwide Children's Hospital, 700 Children's Dr, Columbus, OH, 43205, USA.
Department of Pediatrics, College of Medicine, The Ohio State University, Columbus, OH, USA.
J Autism Dev Disord. 2022 Dec;52(12):5342-5355. doi: 10.1007/s10803-021-05396-9. Epub 2022 Jan 11.
This double-blind, randomized controlled trial, tested fatty acid (FA) supplementation in children (ages 2- < 6 years) recently diagnosed with Autism Spectrum Disorder (ASD). Participants received daily oral FA supplement containing omega-3 and omega-6 FA, or a placebo for 90 days based on participant weight. Erythrocyte FAs and the cytokines, IL-1β, IL-2, IFNγ, were measured in plasma obtained from serial blood collections. Treatment increased omega-3 and omega-6 FA levels (1.40 mol% for EPA and 1.62 mol% for DHA) and reduced IL-2 levels compared to placebo (- 0.17 pg/mL, 95% CI - 0.31, - 0.02, d = - 0.62). Omega 3-6 treatment was tolerable and adherence was greater than 70%. Future research will assess the effects of Omega 3-6 treatment on ASD symptoms. Registered on 06/08/2018 with ClinicalTrials.gov: NCT03550209.
这项双盲、随机对照试验测试了脂肪酸（FA）补充剂在近期被诊断为自闭症谱系障碍（ASD）的儿童（2-<6 岁）中的作用。参与者根据体重每天口服含有欧米伽-3 和欧米伽-6 FA 的 FA 补充剂或安慰剂，持续 90 天。从连续采血中获得的血浆中测量红细胞 FA 和细胞因子 IL-1β、IL-2、IFNγ。与安慰剂相比，治疗增加了 ω-3 和 ω-6 FA 水平（EPA 为 1.40 摩尔%，DHA 为 1.62 摩尔%），并降低了 IL-2 水平（-0.17 pg/mL，95%CI-0.31，-0.02，d=-0.62）。ω-3-6 治疗耐受良好，依从性大于 70%。未来的研究将评估 ω-3-6 治疗对 ASD 症状的影响。于 2018 年 6 月 8 日在 ClinicalTrials.gov 上注册：NCT03550209。
